高级检索
当前位置: 首页 > 详情页

Antagonizing EZH2 combined with vitamin D3 exerts a synergistic role in anti-fibrosis through bidirectional effects on hepatocytes and hepatic stellate cells

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Shanghai Jiao Tong Univ, Shanghai Tongren Hosp, Dept Clin Lab, Sch Med, Shanghai 200336, Peoples R China [2]Shanghai Jiao Tong Univ, Shanghai Tongren Hosp, Dept Gastroenterol, Sch Med, Shanghai 200336, Peoples R China [3]Jiangsu Univ, Kunshan Peoples Hosp 1, Dept Clin Lab, Kunshan, Peoples R China
出处:
ISSN:

关键词: hepatic stellate cell hepatocyte liver fibrosis vitamin D

摘要:
Background and AimWhether vitamin D3 (VD3) supplementation is associated with improved liver fibrosis is controversial. MethodsLiver fibrosis models were treated with VD3, active VD (1,25-OH2 Vitamin D3), or collaboration with GSK126 (Ezh2 inhibitor), respectively. Hepatic stellate cells (HSCs) were co-cultured with hepatocytes and then stimulated with TGF-beta. Autophagy of hepatocytes was determined after the intervention of 1,25-OH2 Vitamin D3 and GSK126. Also, the active status of HSCs and the mechanism with 1,25-OH2 Vitamin D3 and GSK126 intervention were detected. Results1,25-OH2 Vitamin D3, but not VD3, is involved in anti-fibrosis and partially improves liver function, which might be associated with related enzymes and receptors (especially CYP2R1), leading to decreased of its biotransformation. GSK126 plays a synergistic role in anti-fibrosis. The co-culture system showed increased hepatocyte autophagy after HSCs activation. Supplementation with 1,25-OH2 Vitamin D3 or combined GSK126 reduced these effects. Further studies showed that 1,25-OH2 Vitamin D3 promoted H3K27 methylation of DKK1 promoter through VDR/Ezh2 due to the weakening for HSCs inhibitory signal. ConclusionsVD3 bioactive form 1,25-OH2 Vitamin D3 is responsible for the anti-fibrosis, which might have bidirectional effects on HSCs by regulating histone modification. The inhibitor of Ezh2 plays a synergistic role in this process.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 3 区 医学
小类 | 3 区 胃肠肝病学
最新[2023]版:
大类 | 3 区 医学
小类 | 3 区 胃肠肝病学
JCR分区:
出版当年[2021]版:
Q2 GASTROENTEROLOGY & HEPATOLOGY
最新[2023]版:
Q2 GASTROENTEROLOGY & HEPATOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]Shanghai Jiao Tong Univ, Shanghai Tongren Hosp, Dept Clin Lab, Sch Med, Shanghai 200336, Peoples R China [3]Jiangsu Univ, Kunshan Peoples Hosp 1, Dept Clin Lab, Kunshan, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [1]Shanghai Jiao Tong Univ, Shanghai Tongren Hosp, Dept Clin Lab, Sch Med, Shanghai 200336, Peoples R China [2]Shanghai Jiao Tong Univ, Shanghai Tongren Hosp, Dept Gastroenterol, Sch Med, Shanghai 200336, Peoples R China [*1]Department of Clinical Laboratory, Shanghai Tongren Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200336, China [*2]Department of Gastroenterology, Shanghai Tongren Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200336, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:21169 今日访问量:0 总访问量:1219 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)